Myriad's high-quality hereditary cancer tests support a narrow moat.
Narrow-moat Myriad reported fiscal first-quarter 2018 earnings in line with our expectations, and we are maintaining our $30 fair value estimate. Myriad’s hereditary cancer business continues to see pricing pressure from new entrants, and sales in this business fell in the quarter as a result. Given the uncertainty surrounding payer reaction to recent results of a large study of GeneSight, the mental health disorder medication selection test, we’re lowering our GeneSight forecast, offset by mino...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.